Jim Simons Sigilon Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.34 - $1.38 $30,048 - $121,961	-88,378 Reduced 47.74%	96,732 $90,000
Q4 2022 Feb 13, 2023	BUY	$0.29 - $0.69 $8,350 - $19,867	28,794 Added 18.42%	185,110 $65,000
Q3 2022 Nov 14, 2022	SELL	$0.48 - $0.86 $34,537 - $61,879	-71,953 Reduced 31.52%	156,316 $79,000
Q2 2022 Aug 12, 2022	SELL	$0.74 - $1.64 $35,024 - $77,622	-47,331 Reduced 17.17%	228,269 $189,000
Q1 2022 May 13, 2022	BUY	$1.24 - $3.03 $194,294 - $474,767	156,689 Added 131.77%	275,600 $405,000
Q4 2021 Feb 11, 2022	BUY	$2.58 - $6.13 $231,196 - $549,315	89,611 Added 305.84%	118,911 $328,000
Q3 2021 Nov 12, 2021	BUY	$4.42 - $10.61 $129,506 - $310,873	29,300 New	29,300 $166,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.